Bank Of New York Mellon Corp Edgewise Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$6.66 - $11.33 $825,040 - $1.4 Million	123,880 New	123,880 $826 Million
Q4 2022 Feb 14, 2023	BUY	$7.58 - $11.08 $967,928 - $1.41 Million	127,695 New	127,695 $1.14 Million
Q3 2022 Nov 14, 2022	SELL	$8.08 - $13.58 $754,494 - $1.27 Million	-93,378 Reduced 49.34%	95,861 $943,000
Q2 2022 Aug 15, 2022	SELL	$5.67 - $9.87 $134,084 - $233,405	-23,648 Reduced 11.11%	189,239 $1.51 Million
Q1 2022 May 11, 2022	SELL	$9.1 - $18.97 $14,796 - $30,845	-1,626 Reduced 0.76%	212,887 $2.07 Million
Q4 2021 Feb 11, 2022	BUY	$14.41 - $22.41 $2.58 Million - $4.01 Million	179,099 Added 505.73%	214,513 $3.28 Million
Q3 2021 Nov 12, 2021	BUY	$14.11 - $24.1 $97,937 - $167,278	6,941 Added 24.38%	35,414 $588,000
Q2 2021 Aug 11, 2021	BUY	$21.33 - $30.25 $607,329 - $861,308	28,473 New	28,473 $607,000

191

100M

2.17M

410K

Ticker EWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,171,700
Market Cap $1.94B
Description
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.